136 results
425
TCRR
Tcr2 Therapeutics Inc
30 May 23
Business combination disclosure
4:21pm
’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general … ) in connection with the proposed transaction; unknown liabilities related to Adaptimmune or TCR2; the nature, cost and outcome of any litigation and other
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
.
These statements are based on Adaptimmune’s and TCR2’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent … ) in connection with the transaction; unknown liabilities related to Adaptimmune or TCR2; the nature, cost and outcome of any litigation and other legal
8-K
ADAP
Adaptimmune Therapeutics Plc
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
to such statements.
These statements are based on Adaptimmune’s and TCR2’s current plans, estimates and projections. By their very nature, forward-looking … ; the nature, cost and outcome of any litigation and other legal proceedings involving Adaptimmune, TCR2 or their respective directors, including any
8-K
EX-10.1
3lvfnoxd1 99ri
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
438qpek6fan9hrd
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
8-K
EX-10.4
7p27 yto7az
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
9a3qesdks01l9xv
6 Jul 18
Departure of Directors or Certain Officers
5:00pm